Fluorinated Hyaluronic Acid Encapsulated Perfluorocarbon Nanoparticles as Tumor-Targeted Oxygen Carriers to Enhance Radiotherapy

The efficacy of radiotherapy is significantly constricted by tumor hypoxia. To overcome this obstacle, one promising approach is to use the perfluorocarbon-based O2 carriers combined with hyperoxic respiration to relieve tumor hypoxia. However, this passively transported oxygen carrier during hypero...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 19; no. 11; pp. 3948 - 3958
Main Authors Wang, Wenguang, Wang, Xingli, Tao, Feng, Hu, Kaiyuan, Zhang, Junying, Wu, Jinhui, You, Linjun, Zhao, Weijun
Format Journal Article
LanguageEnglish
Published American Chemical Society 07.11.2022
Subjects
radiotherapy
perfluorocarbon nanoparticles
oxygen
tumor-targeting
hyaluronic acid
Online AccessGet full text

Cover

More Information
Summary:The efficacy of radiotherapy is significantly constricted by tumor hypoxia. To overcome this obstacle, one promising approach is to use the perfluorocarbon-based O2 carriers combined with hyperoxic respiration to relieve tumor hypoxia. However, this passively transported oxygen carrier during hyperoxic respiration is prone to cause systemic oxidative stress and toxicity, which further limits its clinical application. Herein, we fabricate O2@PFC@FHA NPs for safe and specific oxygen delivery into tumors by using the fluorinated hyaluronic acid to encapsulate O2-saturated perfluorocarbon. Due to the interaction between HA and CD44 receptors, more FHA@PFC NPs accumulated in the tumor and the O2@PFC@FHA NPs significantly relieved tumor hypoxia. Notably, RT plus O2@PFC@FHA NPs resulted in almost threefold therapeutic improvement compared with RT without obvious systemic toxicity. Therefore, the O2@FHA@PFC NPs may have great potential to enhance the therapeutic efficacy of radiotherapy in the clinic.
ISSN:1543-8384
1543-8392
DOI:10.1021/acs.molpharmaceut.2c00432